AI Article Synopsis
- * Researchers conducted a study using a mouse model to analyze metabolic changes in premalignant and non-muscle invasive bladder cancer (NMIBC), identifying specific metabolic signatures linked to these stages.
- * The findings suggest that lipid metabolism plays a key role in the development of premalignant lesions and NMIBC, and the study provides potential biomarkers for predicting outcomes in human bladder cancer patients.
Article Abstract
Bladder cancer (BCa) is the most common malignancy of the urinary system with increasing incidence, mortality, and limited treatment options. Therefore, it is imperative to validate preclinical models that faithfully represent BCa cellular, molecular, and metabolic heterogeneity to develop new therapeutics. We performed metabolomic profiling of premalignant and non-muscle invasive bladder cancer (NMIBC) that ensued in the chemical carcinogenesis N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN) mouse model. We identified the enriched metabolic signatures that associate with premalignant and NMIBC. We found that enrichment of lipid metabolism is the forerunner of carcinogen-induced premalignant and NMIBC lesions. Cross-species analysis revealed the prognostic value of the enzymes associated with carcinogen-induced enriched metabolic in human disease. To date, this is the first study describing the global metabolomic profiles associated with early premalignant and NMIBC and provide evidence that these metabolomic signatures can be used for prognostication of human disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8585868 | PMC |
| http://dx.doi.org/10.1038/s41598-021-99746-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeting microRNA-145-mediated progressive phenotypes of early bladder cancer in a molecularly defined model.
Mol Ther Nucleic Acids
September 2023
The United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Gifu, Japan.
A progressive subclass of early-stage non-muscle-invasive bladder cancer (NMIBC) frequently recurs and progress into invasive carcinoma, thus decreasing the overall survival rate of NMIBC. However, therapeutic development for progressive NMIBC has been challenging due to the lack of molecularly validated models and agents targeting its genetic vulnerability. We herein molecularly characterized an interventional model of progressive NMIBC and revealed the principal functions and therapeutic potential of microRNA-145 (miR-145) in early bladder tumorigenesis.
View Article and Find Full Text PDFMetabolomic credentialing of murine carcinogen-induced urothelial cancer.
Sci Rep
November 2021
Department of Cancer Biology, Medical Center Boulevard, Wake Forest University School of Medicine, Winston-Salem, NC, 27157, USA.
Article Synopsis
- * Researchers conducted a study using a mouse model to analyze metabolic changes in premalignant and non-muscle invasive bladder cancer (NMIBC), identifying specific metabolic signatures linked to these stages.
- * The findings suggest that lipid metabolism plays a key role in the development of premalignant lesions and NMIBC, and the study provides potential biomarkers for predicting outcomes in human bladder cancer patients.
The dynamics of the inflammatory response during BBN-induced bladder carcinogenesis in mice.
J Transl Med
November 2019
Department of Immunology, School of Medicine, University of Split, 21000, Split, Croatia.
Background: Bladder cancer (BC) is the most common malignant disease of the urinary tract. Recurrent high grade non muscle invasive BC carries a serious risk for progression and subsequent metastases. The most common preclinical mouse model for bladder cancer relies on administration of N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) to mice.
View Article and Find Full Text PDFPharmacokinetics and pharmacodynamics of intravesical and intravenous TMX-101 and TMX-202 in a F344 rat model.
Urol Oncol
May 2018
Department of Urology, Radboud University Medical Center, Nijmegen, the Netherlands.
Objectives: To evaluate and compare the pharmacokinetic and pharmacodynamic properties of 2 investigational Toll-like receptor 7 agonists, TMX-101, and TMX-202 after intravenous and intravesical administration in a rat model. TLR-7 agonists are successfully used as topical treatment for various (pre)malignant skin lesions and are now under investigation as intravesical therapy for non-muscle-invasive bladder cancer.
Methods: Rats received an intravesical instillation with TMX-101, TMX-202, or vehicle.
Monitoring the response of urothelial precancerous lesions to Bacillus Calmette-Guerin at the proteome level in an in vivo rat model.
Cancer Immunol Immunother
January 2018
Department of Urology, Kocaeli University School of Medicine, Umuttepe Campus, 41380, Kocaeli, Turkey.
Intravesical Bacillus Calmette-Guerin (BCG) is the best treatment modality for progression of non-muscle invasive bladder cancer. We aimed to monitor changes at the proteome level to identify putative protein biomarkers associated with the response of urothelial precancerous lesions to intravesical BCG treatment. The rats were divided into three groups (n = 10/group): control, non-treated, and BCG-treated groups.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!